李琦軍邢兆國(guó)常軍英吳永波張淑麗王顏志穆衛(wèi)盧李炎賈東召
·論 著·
神經(jīng)肽Y對(duì)小神經(jīng)膠質(zhì)細(xì)胞活化狀態(tài)和生成IL-1β的影響
李琦軍*邢兆國(guó)*常軍英*吳永波△張淑麗※王顏志*穆衛(wèi)盧*李炎*賈東召*
目的探討神經(jīng)肽Y(NPY)對(duì)原代小神經(jīng)膠質(zhì)細(xì)胞生物活性及生成IL-1β的影響。方法 培養(yǎng)的原代大鼠皮層小膠質(zhì)細(xì)胞,將細(xì)胞分為Control組、LPS組、NPY+LPS組、NPY組和BIBP3226+NPY+LPS組,每組3個(gè)樣本,培養(yǎng)各組細(xì)胞6h。經(jīng)免疫細(xì)胞化學(xué)熒光染色后,顯微鏡下觀察小膠質(zhì)細(xì)胞的形態(tài)學(xué)變化。Eli?sa方法檢測(cè)培養(yǎng)液中IL-1β蛋白含量,RT-PCR方法檢測(cè)小膠質(zhì)細(xì)胞中IL-1βmRNA表達(dá)水平。結(jié)果 孵育各組小膠質(zhì)細(xì)胞 6h后,LPS組培養(yǎng)液中IL-1β蛋白的含量及細(xì)胞中IL-1βmRNA表達(dá)水平分別為(961.00± 83.50)pg/mL和5.59±0.87,顯著高于Control組的96.33±24.58 pg/mL和1.05±0.12(P<0.05),小膠質(zhì)細(xì)胞處于活化狀態(tài);LPS+NPY組IL-1β蛋白含量和mRNA表達(dá)水平分別為(411.33±55.00)pg/mL和1.93±0.45,與LPS組相比顯著降低(P<0.05),小膠質(zhì)細(xì)胞活化水平降低;IBP3226+NPY+LPS組IL-1β蛋白含量和mRNA表達(dá)水平分別為(886.00±97.53)pg/mL和4.51±0.71,與LPS+NPY組相比顯著增高(P<0.05);LPS組和IBP3226+NPY+LPS組之間無(wú)統(tǒng)計(jì)學(xué)意義。NPY組與對(duì)照組無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 NPY通過(guò)作用于NPY Y1受體降低小神經(jīng)膠質(zhì)細(xì)胞的生物活性,抑制其生成IL-1β。
神經(jīng)肽-Y小神經(jīng)膠質(zhì)細(xì)胞 白介素-1β
小膠質(zhì)細(xì)胞是一種廣泛分布于中樞神經(jīng)系統(tǒng)的巨噬細(xì)胞。正常狀態(tài)下,小膠質(zhì)細(xì)胞處于靜息狀態(tài),在中樞神經(jīng)系統(tǒng)中起著免疫監(jiān)視作用。當(dāng)內(nèi)環(huán)境發(fā)生變化時(shí)會(huì)迅速被激活,激活后的小膠質(zhì)細(xì)胞能夠釋放白細(xì)胞介素1β(interleukin-1β,IL-1β)和腫瘤壞死因子α(tumor necrosis factor-α,TNF-α)等細(xì)胞因子以及活性氧、活性氮、脂類等大量生物活性物質(zhì)[1,2],這些活性物質(zhì)的過(guò)分釋放并積聚于中樞神經(jīng)系統(tǒng)會(huì)導(dǎo)致神經(jīng)元損傷[3-5]。神經(jīng)肽Y(NPY)是一種多肽類物質(zhì),廣泛分布于中樞及周圍神經(jīng)系統(tǒng),由36個(gè)氨基酸組成,與癲癇,學(xué)習(xí)和記憶都有著密切關(guān)系,NPY可以通過(guò)NPY Y2、Y5受體起到保護(hù)神經(jīng)元作用。最近Ferreira R等研究[6]表明,NPY可以抑制脂多糖(LPS)所致的小鼠小膠質(zhì)細(xì)胞N9細(xì)胞株的激活,減少IL-1β、NO的生成。本實(shí)驗(yàn)將進(jìn)一步研究NPY對(duì)體外培養(yǎng)的原代大鼠皮層小膠質(zhì)細(xì)胞的生物活性、小膠質(zhì)細(xì)胞來(lái)源的IL-1β生成的影響。
1.1 研究對(duì)象24h內(nèi)新生SD大鼠30只(清潔級(jí),河北醫(yī)科大學(xué)實(shí)驗(yàn)動(dòng)物中心提供[動(dòng)物生產(chǎn)許可證號(hào)SCXK(冀)2013-1-03]。主要試劑:小鼠單克隆抗體IBA-1、脂多糖(美國(guó)Sigma公司),F(xiàn)ITC標(biāo)記的山羊抗小鼠IgG(美國(guó)Proteintech公司),胎牛血清、DMEMF12培養(yǎng)液(美國(guó)Gibco公司),BIBP3226(美國(guó)Tocris Bioscience公司),神經(jīng)肽Y (NPY)(美國(guó)ENZO公司),ELISA試劑盒(中國(guó)Bio-Swamp公司),GoldViewⅠ型核酸染料(美國(guó)Ameresco公司),Trizol(美國(guó) Invitrogen公司),RT-PCR逆轉(zhuǎn)錄試劑盒、RNA酶抑制劑(RNasin)、PCR擴(kuò)增試劑盒、隨機(jī)引物(Random primers)(美國(guó)Promega公司)。
1.2 小膠質(zhì)細(xì)胞培養(yǎng)參照Nakajima等[7]所述方法。24h內(nèi)新生大鼠無(wú)菌環(huán)境下開(kāi)顱取腦,剝除腦膜及血管,取部分大腦皮質(zhì),剪碎用0.125%胰蛋白酶37℃消化15 min,反復(fù)吹打成懸液,1000 r/min離心5 min后過(guò)濾,棄上清,在沉淀物中加入膠質(zhì)細(xì)胞培養(yǎng)液(膠質(zhì)細(xì)胞培養(yǎng)液為含10%胎牛血清,1U/mL青霉素、100μg/mL鏈霉素的DMEM/F12培養(yǎng)基制成細(xì)胞懸液),接種于250mL培養(yǎng)瓶中,37℃,5%CO2培養(yǎng)。第2天全量換液一次,以后每3d更換1/2體積培養(yǎng)液。培養(yǎng)至第14天,細(xì)胞充分分層生長(zhǎng)后,置于37℃恒溫?fù)u床中180r/min振搖2h,收集細(xì)胞懸液,1000r/min離心5min,去上清,用DMEM/F12全培養(yǎng)基吹打成細(xì)胞懸液,將細(xì)胞調(diào)至約1×105/mL,種植到預(yù)先鋪好多聚賴氨酸的六孔板內(nèi),每孔3mL。在恒溫培養(yǎng)箱內(nèi)靜置30min后完全換液一次,去除少突膠質(zhì)細(xì)胞,加入DMEM/F12完全培養(yǎng)基繼續(xù)培養(yǎng)3~5d。
1.3 形態(tài)學(xué)觀察分離純化好的小膠質(zhì)細(xì)胞分別以1×104個(gè)/皿接種于3個(gè)預(yù)先放置經(jīng)多聚賴氨酸處理過(guò)的蓋玻片的3.5cm培養(yǎng)皿,24h后,分別更換為無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液、含脂多糖(LPS)(終濃度為100ng/mL)的無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液、含NPY(終濃度為1μmol/L)及LPS(終濃度為100ng/ mL)的無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液繼續(xù)培養(yǎng)6h,取出蓋玻片,以IBA-1為一抗,行免疫細(xì)胞化學(xué)染色,熒光顯微鏡下觀察原代大鼠皮質(zhì)小膠質(zhì)細(xì)胞形態(tài)學(xué)變化。
1.4 小膠質(zhì)細(xì)胞分組及處理方法將分離純化好的小膠質(zhì)細(xì)胞以2×104個(gè)/孔接種于預(yù)鋪多聚賴氨酸的24孔培養(yǎng)板用于IL-1β蛋白檢測(cè),以5×105個(gè)/孔接種于6孔培養(yǎng)板用于IL-1βmRNA的檢
測(cè)。培養(yǎng)3d后換新鮮無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液培養(yǎng)12h使細(xì)胞同步化,然后將細(xì)胞分為Control組、LPS組、NPY+LPS組、NPY組和BIBP3226+NPY+ LPS組,每組3個(gè)樣本。Control組細(xì)胞以無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液孵育6h,LPS組細(xì)胞以含終濃度為100ng/mL LPS的無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液孵育6h,NPY+LPS組細(xì)胞是先以含NPY(終濃度為1μmol/ L)的無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液孵育0.5h,然后加入LPS(終濃度為100ng/mL)繼續(xù)孵育6h。NPY組細(xì)胞以含NPY(終濃度為1μmol/L)無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液孵育6h。IBP3226+NPY+LPS組細(xì)胞先用含NPY Y1受體阻斷劑BIBP3226(終濃度為1 μmol/L)的無(wú)血清膠質(zhì)細(xì)胞培養(yǎng)液孵育0.5h,再加入終濃度為1μmol/L的NPY孵育0.5h,最后加入終濃度100ng/mL的LPS繼續(xù)孵育6h。
1.5 小膠質(zhì)細(xì)胞培養(yǎng)液中IL-1β蛋白含量的檢測(cè)取上述各組小膠質(zhì)細(xì)胞培養(yǎng)液,離心后采用ELI?SA法檢測(cè)培養(yǎng)液中IL-1β蛋白含量。
1.6 小膠質(zhì)細(xì)胞中IL-1βmRNA表達(dá)水平的檢測(cè)采用實(shí)時(shí)熒光定量PCR法檢測(cè)上述各組小膠質(zhì)細(xì)胞中的IL-1βmRNA表達(dá)水平。小膠質(zhì)細(xì)胞加入Trizol(1mL/孔),吹打后移至去核酶的離心管中,靜置5min。每管加入0.2mL氯仿,震蕩15s,靜置5min。12000r/min離心15min,把上層無(wú)色液體移到新的離心管中。加入等體積的異丙醇,顛倒混勻。4℃12000r/min離心10min,管底可見(jiàn)羽毛狀白色沉淀物,完全棄去上清。加入1mL 75%乙醇(DEPC水配置),洗滌沉淀。4℃7500r/min離心5min,棄上清。靜置晾干3~5min,加入20~30 μL DEPC水充分溶解RNA。1%瓊脂糖凝膠電泳證實(shí)RNA完整性較好,無(wú)污染。紫外分光光度計(jì)檢測(cè)RNA濃度。引物由上海生工生物公司合成。IL-1β上游引物5’-CTCCATGAGC TTTGTA?CAAGG-3’,IL-1β下游引物5’-TGCTGATGTAC?CAGTTGGG-3’,擴(kuò)展長(zhǎng)度為245bp。GAPDH上游引物 5’-TGAACGGGAAGCTCACTGG-3’,GAPDH下游引物5’-GCTTCACCACCTTCTTGAT?GTC-3’,擴(kuò)增長(zhǎng)度為120bp。實(shí)時(shí)PCR反應(yīng)中反轉(zhuǎn)錄反應(yīng)體系總RNA 8μL,隨機(jī)引物1μL,2×ES Reaction Mix 10μL,RT/RI Enzyme Mix 1μL,總體積20μL。擴(kuò)增體系為:2×UltraSYBR Mixture(with ROX)10μL,上游引物(10μmol/L)1μL,下游引物(10μmol/L)1μL,cDNA 8μL,總 體 積 20μL。RT-PCR反應(yīng)程序參數(shù):預(yù)變性95℃10min;變性95℃ 15s,退火58℃ 20s,延伸72℃ 27s,40個(gè)循環(huán)。用ABI 7300 Real-Time PCR System((Applied Biosystems,Foster City,CA,USA)檢測(cè)并計(jì)算目的基因表達(dá)量與內(nèi)參GAPDH比較的相對(duì)值(RQ值),用于統(tǒng)計(jì)分析。
1.7 統(tǒng)計(jì)學(xué)方法利用SPSS10.0進(jìn)行統(tǒng)計(jì)學(xué)處理,經(jīng)正態(tài)性檢驗(yàn)和方差齊性檢驗(yàn),數(shù)據(jù)符合正態(tài)性和方差齊性的要求,采用完全隨機(jī)設(shè)計(jì)的方差分析,進(jìn)一步的兩兩比較采用LSD法,數(shù)據(jù)以±s表示,檢測(cè)水準(zhǔn)α=0.05。
2.1 大鼠大腦皮質(zhì)小膠質(zhì)細(xì)胞的形態(tài)學(xué)變化無(wú)血清培養(yǎng)液孵育的小膠質(zhì)細(xì)胞呈細(xì)胞呈分枝狀外觀,胞體較小,有細(xì)長(zhǎng)的突起(箭頭),細(xì)胞表達(dá)IBA-1(圖1)。含LPS的無(wú)血清培養(yǎng)液孵育的小膠質(zhì)細(xì)胞處于活化狀態(tài),胞體變?yōu)閳A形和阿米巴狀,突起回縮,IBA-1染色加深(箭頭,圖2)。提前加入NPY再加入LPS的無(wú)血清培養(yǎng)液孵育的小膠質(zhì)細(xì)胞大部分為非活化狀態(tài),成多角形,有長(zhǎng)的突起(箭頭),IBA-1染色陽(yáng)性,但比LPS組熒光強(qiáng)度明顯弱(圖3)。
2.2 培養(yǎng)液中IL-1β蛋白含量的變化孵育各組小膠質(zhì)細(xì)胞6h后,LPS組和IBP3226+NPY+LPS組中IL-1β的含量顯著高于Control組(F=127.991, P<0.05);LPS組和IBP3226+NPY+LPS組之間無(wú)顯著性差異。LPS+NPY組與LPS組相比,培養(yǎng)液中IL-1β含量顯著降低(P<0.05),IBP3226+NPY+ LPS組與LPS+NPY組相比,培養(yǎng)液中IL-1β的含量顯著增高(P<0.05),NPY組與對(duì)照組無(wú)統(tǒng)計(jì)學(xué)意義。見(jiàn)表1。
2.3 小膠質(zhì)細(xì)胞中IL-1βmRNA水平的變化孵育各組小膠質(zhì)細(xì)胞6h后,LPS組和BIBP3226+ NPY+LPS組小膠質(zhì)細(xì)胞的IL-1βmRNA表達(dá)水平顯著高于Control組(F=42.4712,P<0.05);LPS組和IBP3226+NPY+LPS組之間無(wú)顯著性差異。與
LPS組相比,LPS+NPY組小膠質(zhì)細(xì)胞中的IL-1βmRNA表達(dá)水平明顯降低(P<0.05)。與LPS+NPY組相比,IBP3226+NPY+LPS組小膠質(zhì)細(xì)胞中的IL-1βmRNA表達(dá)水平顯著增高(P<0.05),NPY組與對(duì)照組無(wú)統(tǒng)計(jì)學(xué)意義。見(jiàn)表1。
自從Besedovsky提出了免疫-神經(jīng)-內(nèi)分泌調(diào)節(jié)網(wǎng)絡(luò)學(xué)說(shuō)以來(lái),免疫在神經(jīng)系統(tǒng)疾病中的作用受到人們?cè)絹?lái)越多的關(guān)注。小膠質(zhì)細(xì)胞(MG)廣泛分布于中樞神經(jīng)系統(tǒng),在免疫功能調(diào)節(jié)方面起著重要作用。很多資料顯示小膠質(zhì)細(xì)胞激活和中樞神經(jīng)系統(tǒng)很多疾病有關(guān),例如阿爾茨海默病、帕金森綜合癥、腦缺血等中樞神經(jīng)系統(tǒng)病變[8-10]。MG活化后產(chǎn)生大量細(xì)胞因子等生物活性物質(zhì),例如IL-1β、TNF-a、NO等,這些物質(zhì)的大量積聚會(huì)對(duì)神經(jīng)元產(chǎn)生毒害作用,這可能是MG活化后導(dǎo)致神經(jīng)元損傷的重要途徑之一。IL-1β是最常見(jiàn)的損傷性細(xì)胞因子,也是小膠質(zhì)細(xì)胞激活后釋放的前炎癥因子,在中樞神經(jīng)系統(tǒng)多種生理和病理過(guò)程中發(fā)揮著重要作用。
圖1 無(wú)血清培養(yǎng)基孵育的小膠質(zhì)細(xì)胞,IBA-1染色后的小膠質(zhì)細(xì)胞,可見(jiàn)長(zhǎng)的突起(400×),標(biāo)尺為25μm
圖2 含LPS的無(wú)血清培養(yǎng)基孵育的小膠質(zhì)細(xì)胞,IBA-1染色加深,胞體突起回縮,成圓形或者多角形(400×),標(biāo)尺為25μm
圖3 含LPS和NPY的無(wú)血清培養(yǎng)基孵育的小膠質(zhì)細(xì)胞,IBA-1染色后大部分細(xì)胞有長(zhǎng)的細(xì)胞突起,熒光強(qiáng)度較LPS組明顯減弱(400×),標(biāo)尺為25μm
表1 各組培養(yǎng)基中IL-1β蛋白含量(±s,n=3)
表1 各組培養(yǎng)基中IL-1β蛋白含量(±s,n=3)
1)與control組比較,P<0.05;2)與LPS+NPY組比較,P<0.05
?
人體內(nèi)的神經(jīng)肽類物質(zhì)與炎癥反應(yīng)有著較密切的關(guān)系。當(dāng)體內(nèi)出現(xiàn)炎癥反應(yīng)時(shí)會(huì)釋放一些神經(jīng)肽類物質(zhì),這些神經(jīng)肽類物質(zhì)可以下調(diào)機(jī)體的免疫應(yīng)答,誘導(dǎo)T細(xì)胞的產(chǎn)生,抑制抗原特異性Th1細(xì)胞分化,維持機(jī)體免疫耐受,減輕炎癥反應(yīng)[11-14]。NPY全名神經(jīng)肽酪氨酸,是一種廣泛存在于中樞神經(jīng)系統(tǒng)中的神經(jīng)肽,與癲癇,學(xué)習(xí)、記憶、攝食和內(nèi)分泌都有著密切關(guān)系。NPY通過(guò)與不同的受體結(jié)合在體內(nèi)發(fā)揮不同的作用,NPY受體都屬于G蛋白的偶聯(lián)受體,在人體內(nèi)包括Y1、Y2、Y3、Y4、Y5 5種亞型。第二軍醫(yī)大學(xué)周江睿對(duì)原代培養(yǎng)的腹腔巨噬細(xì)胞和RAW264.7細(xì)胞的研究[15]顯示,NPY對(duì)炎癥因子的調(diào)節(jié)具有雙面性,一方面,NPY能夠抑制腹腔巨噬細(xì)胞釋放炎性因子IL-1β、TNF-α、IL-6和前列腺素B2,另一方面,NPY能夠促進(jìn)腹腔巨噬細(xì)胞晚期炎癥因子HMGB1的分泌。最近Ferreira R等[16-17]研究表明,小鼠小神經(jīng)膠質(zhì)細(xì)胞株N9細(xì)胞表達(dá)NPYY1受體,NPY可以抑制LPS所致N9細(xì)胞的激活,減少
IL-1β、NO的生成,另一方面,NPY還能抑制N9細(xì)胞的吞噬作用和遷移能力,當(dāng)阻斷NPY Y1受體后,這種抑制作用消失。本實(shí)驗(yàn)采用LPS為MG的激活劑,在LPS處理MG 6h后,MG處于明顯的活化狀態(tài),細(xì)胞體積增大,突觸回縮,由分支狀變?yōu)閳A形、梭形或者阿米巴狀,特征性標(biāo)志物IBA-1免疫染色加深,MG的免疫活性也隨之增強(qiáng),MG培養(yǎng)液中IL-1β含量與MG細(xì)胞中IL-1βmRNA表達(dá)水平均明顯增高,與對(duì)照組有顯著差異。加入NPY后能夠明顯抑制LPS對(duì)MG的激活作用,使大部分MG處于非活化狀態(tài),降低了MG培養(yǎng)液中IL-1β蛋白和MG細(xì)胞內(nèi)的IL-1βmRNA表達(dá)水平,使用BIBP3226阻斷NPY Y1受體后這種抑制作用完全消失,說(shuō)明NPY是通過(guò)Y1受體起到降低MG的免疫活性,減少M(fèi)G來(lái)源的IL-1β產(chǎn)生。NPY處理非活化的小膠質(zhì)細(xì)胞后,培養(yǎng)液中IL-1βa蛋白及MG細(xì)胞內(nèi)的IL-1βmRNA水平均未發(fā)生明顯變化,說(shuō)明NPY對(duì)靜止期的小膠質(zhì)細(xì)胞影響不大。
本研究表明,NPY對(duì)中樞神經(jīng)系統(tǒng)內(nèi)的小膠質(zhì)細(xì)胞的免疫活性有調(diào)節(jié)作用,NPY能下調(diào)中樞神經(jīng)系統(tǒng)內(nèi)小膠質(zhì)細(xì)胞的免疫活性,抑制IL-1β的產(chǎn)生,這種作用是通過(guò)其Y1受體實(shí)現(xiàn)的。本研究為NPY以小膠質(zhì)細(xì)胞為靶點(diǎn)治療與免疫有關(guān)的中樞神經(jīng)系統(tǒng)疾病提供了實(shí)驗(yàn)依據(jù)。
[1]Wu C Y,Kaur C,Sivakumar V,et al.Kv1.1 expression in mi?croglia regulates production and release of proinflammatory cyto?kines,endothelins and nitric oxide[J].Neuroscience,2009,158 (4):1500-1508.
[2]Mayer A M S,Clifford J A,Aldulescu M,et al.Cyanobacterial Microcystis aeruginosa lipopolysaccharide elicits release of su?peroxide anion,thromboxane B2,cytokines,chemokines,and matrix metalloproteinase-9 by rat microglia[J].Toxicol Sci, 2011,121(1):63-72.
[3]Auvin S,Mazarati A,Shin D,et al.Inflammation enhances epi?leptogenesis in the developing rat brain[J].Neurobiol Dis,2010, 40(1):303-310.
[4]Friedman A,Dingledine R.Molecular cascades that mediate the influence of inflammation on epilepsy[J].Epilepsia,2011,52 (s3):33-39.
[5]Vezzani A,Maroso M,Balosso S,et al.IL-1 receptor/Toll-like receptor signaling in infection,inflammation,stress and neurode?generation couples hyperexcitability and seizures[J].Brain Be?have Immun,2011,25(7):1281-1289.
[6]Ferreira R,Xapelli S,Santos T,et al.Neuropeptide Y modula?tion of interleukin-1β(IL-1β)-induced nitric oxide production in microglia[J].J Biol Chem,2010,285(53):41921-41934.
[7]Nakajima K,Takemoto N,Kohsaka S.Retinoic acid enhances the secretion of plasminogen from cultured rat microglia[J]. FEBS lett,1992,314(2):167-170.
[8]Hickman SE,Allison EK,ElKhoury J.Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice[J].J Neurosci,2008,28(33):8354-8360.
[9]Lilia MM,Mona S,Lauren B,et al.Relationship between microg?lial activation and dopaminergic neuronal loss in the substantia nigra:a time course study in a 6-hydroxydopamine model of Parkinson's disease[J].J Neurochem,2009,110(3):966-975.
[10]Amaia M,Miroslav,Fernando PC,et al.Increased expression of glutamate transporters in subcortical white matter after transient focal cerebral ischemia[J].Neurobiol Dis,2010,37(1):156-165.
[11]Gonzalez-Rey E,Delgado M.Anti-inflammatory neuropeptide receptors:new therapeutic targets for immune disorders?[J]. Trends Pharmacol Sci,2007,28(9):482-491.
[12]Delgado M,Ganea D.Anti-inflammatory neuropeptides:a new class of endogenous immunoregulatory agents[J].Brain Behav Immun,2008,22(8):1146-1151.
[13]Dello Russo C,Lisi L,Navarra P,et al.Diverging effects of cor?tistatin and somatostatin on the production and release of pros?tanoids from rat cortical microglia and astrocytes[J].J Neuroim?munol,2009,213(1):78-83.
[14]Prasse A,Zissel G,Lu¨tzen N,et al.Inhaled vasoactive intesti?nal peptide exerts immunoregulatory effects in sarcoidosis[J]. Am J Respir Crit Care Med,2010,182(4):540-548.
[15]周江睿,蔣春雷.神經(jīng)肽Y對(duì)巨噬細(xì)胞炎癥因子和小分子炎癥介質(zhì)的調(diào)節(jié)及機(jī)制研究[D].上海:第二軍醫(yī)大學(xué),2012-07-19.
[16]Ferreira R,Santos T,Cortes L,et al.Neuropeptide Y inhibits in?terleukin-1 beta-induced microglia motility[J].J Neurochem, 2012,120(1):93-105.
[17]Ferreira R,Santos T,Viegas M,et al.Neuropeptide Y inhibits interleukin-1b-induced phagocytosis by microglial cells[J].J Neuroinflammation,2011,8(2):169.
The effect of NPY on the activation of microglia and IL-1βproduction
.LI Qijun,XING Zhaoguo,CHANGJunying,WU Yongbo,ZHANG Shuli,WANG Yanzhi,MU Weilu,LI Yan,JIA Dongzhao.Department of Orthopaedic Trauma, the third Hospital of Shijiazhuang city,NO.15,South Sports street,Shijiazhuang 050011,China.Tel:0311-85990917.
ObjectiveTo explore the effect of NPY on activation of primary microglia and the production of in?terleukin-1β.MethodsRat primary cortical microglia was cultured and divided into control group,LPS group,NPY+ LPS group,NPY group and BIBP3226+NPY+LPS group.Microglia in control group were incubated with serum-free me?dium for 6 h;microglia in LPS group were incubated with serum-free medium plus LPS for 6 h;microglia in NPY+LPS group were incubated with serum-free medium plus NPY and LPS for 6 h;microglia cells in NPY group were incubat?ed in serum-free medium plus NPY for 6 h;microglia cells in BIBP3226+NPY+LPS group were incubated in se?rum-free medium including BIBP3226、NPY and LPS for 6 h.After 6 h,Primary cultured microglia were stained us?ing IBA-1 antibody and examined under the fluorescence microscope.The protein levels of IL-1βin the culture media and the mRNA expression levels of IL-1 βin the microglia of different groups were detected using the methods of Elisa and RT-PCR.ResultsAfter 6 h,the contents of IL-1 βin the culture media and the mRNA expression levels of IL-1 βin the cells of LPS group increased remarkably compared with control group(P<0.05)and the microglia were activat?
Neuropeptide Y MicrogliaInterleukin-1β
R741
A
2014-06-19)
(責(zé)任編輯:甘章平)
10.3936/j.issn.1002-0152.2015.03.007
* 石家莊市第三醫(yī)院創(chuàng)傷一科(石家莊 050011)
△ 石家莊市公安局法醫(yī)損傷檢驗(yàn)鑒定室
※ 秦皇島市骨科醫(yī)院藥劑科
ed.Compared with LPS group,the contents of IL-1 βin the culture media.the mRNA expression levels of IL-1β and the activity of microglia in LPS+NPY group were significantly decreased.Compared with LPS+NPY group,the contents of IL-1 βin the culture media.the mRNA expression levels of IL-1β and the activity of microglia in BIBP3226+NPY+ LPS group were increased(P<0.05).There were no significant differences in the contents of IL-1βin the culture media. the mRNA expression levels of IL-1β and the activity of microglia between BIBP3226+NPY+LPS group and LPS group or between NPY group and the control group.ConclusionNPY can inhibit the biological activity of microglia and IL-1βproduction through NPY Y1 receptorin the microglia.